SCHEMBL14746133

SCHEMBL14746133

CCCc1ccc2c(c1)cc(-c1[nH]c(=O)cc(O)c1CC)n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 9/20 0.39
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
KDM4E B2RXH2 3/20 0.34
HPGD P15428 3/20 0.34
MEN1 O00255 2/20 0.34
ALOX15 P16050 2/20 0.34
KMT2A Q03164 2/20 0.34
GAA P10253 2/20 0.34
CASP1 P29466 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33
UNG P13051 1/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2C19 P33261 2/20 0.32
DAO P14920 1/20 0.32
MAPK14 Q16539 1/20 0.32
CYP2D6 P10635 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745614 0.93 DAO (0.39) GPR84KDM4EHPGDMEN1ALOX15
SCHEMBL14746849 0.91 GPR84 (0.39) GPR84CNR1CNR2KDM4EHPGD
SCHEMBL14746854 0.85 KDM4E (0.41) KDM4EHPGDMEN1KMT2AHSD17B10
SCHEMBL14745385 0.84 DAO (0.41) GPR84KDM4EHPGDMEN1KMT2A
SCHEMBL14745387 0.81 PDE9A (0.34) GPR84KDM4EHPGDMEN1ALOX15
SCHEMBL14745124 0.77 DAO (0.33) KDM4EDAO
SCHEMBL16428129 0.76 CA2 (0.43) MEN1KMT2AGAANPSR1
SCHEMBL16428798 0.74 MEN1 (0.38) KDM4EHPGDMEN1ALOX15KMT2A
SCHEMBL14745213 0.73 PDE9A (0.37) KDM4EHPGDMEN1ALOX15KMT2A
SCHEMBL14741237 0.72 PDE9A (0.32) GPR84KDM4EMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP GPR84 4656/4885CNR1 4586/4885CNR2 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.